National Institute of Health (NIH) scientists have made a significant breakthrough in understanding how "bad" cholesterol, known as low-density lipoprotein-cholesterol or LDL-C, builds up in the body.

A collection of research by Helen Hobbs, MD, highlights how genetic mutations influence cholesterol levels and impact heart disease risk, offering insights into lifelong cardiovascular health ...

In 1985, the Nobel Prize in Physiology or Medicine was awarded to Michael Brown and Joseph Goldstein for identifying the receptor that clears LDL particles from the bloodstream. High blood levels of ...

Millions of different genes play a role in cholesterol levels. Most of those genetic variants have just a small impact. However, about 1 in 250 people have gene mutations that cause a severe form of ...

Low-density lipoprotein receptor-related protein 4 (LRP4) has emerged as a central modulator of skeletal patterning and homeostasis through its capacity to regulate canonical Wnt/β-catenin signalling.

Researchers have developed a DNA-based therapy that targets the PCSK9 gene to lower cholesterol naturally. Using polypurine hairpins, they increased cholesterol uptake by cells and reduced ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

What Is Lerochol, and Why Does It Matter? Lerochol (lerodalcibep-liga) is a new medicine approved by the FDA to help lower elevated levels of low-density lipoprotein cholesterol (LDL-C), often called ...

Enlicitide, an oral PCSK9 inhibitor, reduced LDL-C by nearly 60% in adults with or at risk for ASCVD. The medication offers a daily oral alternative to injectable PCSK9 inhibitors, potentially ...